Useful information for Healthcare Professionals (HCP) to learn more about the basics of CUP (cancer of unknown primary) including epidemiology, pathogenesis, diagnostic work-up and therapeutic options of patients.

Cup Syndrome

In this section you can find useful information to learn more about the basics of CUP (cancer of unknown primary) including epidemiology, pathogenesis, diagnostic work-up and therapeutic options.

Comprehensive Genomic Profiling

In this section you will learn about comprehensive genomic profiling (CGP) and the promise this approach holds in translating genomic data into clinically useful information. It may help to identify more specific treatment options for patients with CUP.

CUPISCO Study

In this section you will be introduced to the CUPISCO study. This clinical trial aims to determine the efficacy and safety of targeted therapies and cancer immunotherapies for patients with a subset of CUP syndrome. The selection of therapies is based on results from comprehensive genomic profiling.

Are you aware of the unknown?

CUP (cancer of unknown primary) syndrome is defined as a cancer for which only metastases but no primary tumour or site of origin are detectable at the end of a diagnostic and clinical work-up.

How to discover more about the unknown?

Comprehensive genomic profiling (CGP) is a promising approach to translating genomic data into clinically useful information. It may help to identify more specific treatment options for patients with CUP.

Can we improve outcomes in CUP?

So far, data from standard chemotherapy-based clinical trials report median survival times of around one year or less. However, there are options for innovative new clinical trials that explore how to improve outcomes for patients today and in future.^1,2

1. Fizazi K et al. Ann Oncol 2015; 26 (suppl 5): v133–8.
2. Hainsworth JD and Greco FA. American Society of Clinical Oncology Educational Book 38 (May 23, 2018) 20–5.